Brand Name

Eptifibatide

View Brand Information
FDA approval date: December 08, 2015
Classification: Platelet Aggregation Inhibitor
Form: Injection

What is Eptifibatide?

Eptifibatide Injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome managed medically or with percutaneous coronary intervention .

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Therapeutic Plasma Exchange for Uncontrollable Bleeding After Platelet Inhibition with Ticagrelor: A Report of 2 Cases.
Therapeutic Plasma Exchange for Uncontrollable Bleeding After Platelet Inhibition with Ticagrelor: A Report of 2 Cases.
Journal: The American journal of case reports
Published: March 22, 2026
Safety and Feasibility of Same-Admission Transcarotid Arterial Revascularization Prior to Heart Surgery for Patients Presenting With Concurrent, Severe Carotid Artery Stenosis, and Surgical Cardiac Disease.
Safety and Feasibility of Same-Admission Transcarotid Arterial Revascularization Prior to Heart Surgery for Patients Presenting With Concurrent, Severe Carotid Artery Stenosis, and Surgical Cardiac Disease.
Journal: HCA healthcare journal of medicine
Published: March 11, 2026
Glycoprotein IIb/IIIa Agents in Acute Ischemic Stroke: A Niche in the Making?
Glycoprotein IIb/IIIa Agents in Acute Ischemic Stroke: A Niche in the Making?
Journal: Stroke
Published: February 23, 2026
View All Latest Advances